Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future Małgorzata ŁobockaKrystyna DąbrowskaAndrzej Górski Leading Article Open access 21 April 2021 Pages: 255 - 280
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success Salvatore FiorenzaCameron J. Turtle Review Article 07 April 2021 Pages: 281 - 302
Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration Hannah J. YuCharles C. Wykoff Review Article 24 April 2021 Pages: 303 - 323
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study Irene MarafiniCarmine StolfiGiovanni Monteleone Original Research Article Open access 19 April 2021 Pages: 325 - 336
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial Binghe XuQingyuan ZhangHLX02-BC01 Investigators Original Research Article Open access 07 April 2021 Pages: 337 - 350
Evolving Biosimilar Clinical Requirements: A Qualitative Interview Study with Industry Experts and European National Medicines Agency Regulators Louise C. DruedahlSofia Kälvemark SporrongAnna Birna Almarsdóttir Original Research Article 08 April 2021 Pages: 351 - 361
Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey Allison R. KolbeAaron KearsleyAmber Jessup Original Research Article 07 April 2021 Pages: 363 - 372
Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database” Joerg PutzkeScott HaughieGopinath M. Ranganna Letter to the Editor Open access 16 April 2021 Pages: 373 - 374
Author’s Reply to Joerg Putzke et al. Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database” Jingjing QianCong Bang TruongKaniz Afroz Tanni Letter to the Editor 16 April 2021 Pages: 375 - 377